CLLS (Cellectis S.A.) Kacepetan wutah bathi saben saham ing taun lumaku

Lambang korporat lan logo Cellectis S.A. (CLLS)

Cellectis S.A. (CLLS) is a pioneer in gene editing, developing universal cellular methods for mass treatment. The annual earnings per share growth rate captured this trend, with the value stabilizing at -19.70. Proprietary manufacturing facilities in France and the US ensure stability, while TALEN patent protections and FDA certification create a significant barrier to entry for new players.

CLLS: Wutah bathi saben saham ing taun lumaku Cellectis SA 04.07.2022 - 11.11.2026

Rincian metrik keuangan lan pasar cellectis.com (CLLS)

- rega lan prakiraan konsensus rega:
Kutipan saham Cellectis|CLLS - Prakiraan konsensus analis
- indikator valuasi pasar bisnis:
Nilai pasar CLLS|CLLS - Nilai Total Perusahaan
- data ekuitas miturut neraca:
Aset Bersih saben Siji Saham Cellectis S.A.|CLLS - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku cellectis.com|CLLS - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi Cellectis S.A.|CLLS - Utang jangka dawa marang modal|Tanggungan utang jangka cendhak marang ekuitas Cellectis|CLLS - Gunggung utang perusahaan|Utang-utang marang nilai buku CLLS|CLLS - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Cellectis S.A.|Likuiditas darurat cellectis.com
- informasi bathi lan kelipatan valuasi:
CLLS - Penghasilan resik|Penghasilan resik sing dikarepake Cellectis S.A.|CLLS - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep Cellectis|CLLS - Pangali PEG|Nilai bisnis marang bathi operasional sadurunge panyusutan CLLS|CLLS - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan Cellectis S.A.|CLLS - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan cellectis.com|CLLS - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Cellectis S.A.
Pambiji fundamental:CLLS Cellectis Biotherapeutics
Produk sing diprodhuksi Cellectis

To objectively assess the operational efficiency of Cellectis S.A. (CLLS), investors must track the business's actual returns through the lens of net income. The GURU.Markets toolkit calculates the percentage deviation of current earnings per share from the previous year's figures, and such year-over-year earnings per share dynamics will confirm the ability of scalable genome editing technologies to generate superprofits against fixed R&D costs.

Pesaing utama

Wutah bathi resik saben saham ing taun iki Legend Biotech Corp|SANA (Sana Bio) - Wutah bathi ing taun lumaku|Kacepetan wutah bathi saben saham ing taun lumaku Autolus Corp AUTL|Wutah bathi saben saham ing taun lumaku Allogene Therapeutics (ALLO)|Wutah bathi saben saham ing taun lumaku RNAC (selectabio.com)|Wutah bathi saben saham ing taun lumaku Caribou Biosciences, Inc. CRBU|Instil Bio Inc. - Wutah bathi saben saham ing taun lumaku|GNTA: Wutah bathi resik saben saham ing taun iki|Tambahing bathi saben saham ing taun lumaku IPSC (Century Therapeutics)|JSPR: Wutah bathi ing taun lumaku|Owah-owahan bathi resik saben saham ing taun lumaku Senti Biosciences SNTI|ADAP (Adaptimmune Therapeutics plc) - Wutah bathi ing taun lumaku|Kacepetan wutah bathi saben saham ing taun lumaku CERo Therapeutics Holdings Inc. CERO|Wutah bathi saben saham ing taun lumaku Alaunos Therapeutics (TCRT)|achillestx.com - Wutah bathi saben saham ing taun iki|Wutah bathi ing taun lumaku CRGX (CARGO Therapeutics)|poseida.com (PSTX) - Kacepetan wutah bathi saben saham ing taun lumaku|TSVT: Wutah bathi resik saben saham ing taun iki|Tambahing bathi saben saham ing taun lumaku GRCL (Gracell Bio)